Sarris A, Dimopoulos M, Pugh W, Cabanillas F
University of Texas M. D. Anderson Cancer Center, Houston, USA.
J Urol. 1995 Jun;153(6):1852-4. doi: 10.1016/s0022-5347(01)67330-0.
Primary lymphoma of the prostate was diagnosed in 3 patients corresponding to 0.1% of those with previously untreated lymphoma and 0.09% of those with previously untreated prostatic malignancy presenting to our cancer center between January 1, 1980 and December 31, 1993. All 3 patients had prostatism at presentation that caused renal failure in 2. After treatment with doxorubicin-based combination chemotherapy appropriate for the stage and the specific histological subtype, all 3 patients achieved a complete remission and remained free of disease after a minimum followup of 3 years. Our results suggest that primary prostatic lymphoma is not necessarily associated with a poor outcome. Review of the literature suggests that the poor prognosis reported for prostatic lymphoma might be explained by treatment that was acceptable at the time but would be considered suboptimal by current criteria. We recommend thorough staging in all patients with prostatic lymphoma and treatment with a doxorubicin-based regimen according to disease stage and histological classification.
1980年1月1日至1993年12月31日期间,在我院癌症中心就诊的初治淋巴瘤患者中,有3例被诊断为原发性前列腺淋巴瘤,占比0.1%;在初治前列腺恶性肿瘤患者中,这3例占比0.09%。所有3例患者初诊时均有前列腺增生症状,其中2例导致肾衰竭。采用适合疾病分期和特定组织学亚型的含阿霉素联合化疗方案治疗后,所有3例患者均实现完全缓解,且在至少3年的随访期后仍无疾病复发。我们的结果表明,原发性前列腺淋巴瘤不一定预后不良。文献回顾显示,既往报道的前列腺淋巴瘤预后不良可能是当时可接受但按现行标准属于次优的治疗方式所致。我们建议对所有前列腺淋巴瘤患者进行全面分期,并根据疾病分期和组织学分类采用含阿霉素的方案进行治疗。